{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:04:25Z","timestamp":1790777065684,"version":"4.1.0"},"reference-count":46,"publisher":"Baskent University","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.6002\/ect.2020.0342","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T09:16:01Z","timestamp":1618996561000},"page":"473-480","source":"Crossref","is-referenced-by-count":18,"title":["Levosimendan for Treatment of Primary Graft Dysfunction After Heart Transplantation: Optimal Timing of Application"],"prefix":"10.6002","volume":"19","author":[{"given":"Moritz Benjamin","family":"Immohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Akhyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Boettger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Erbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Westenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scheiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tudorache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hug","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Lichtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Boeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. doi:10.1016\/j.jacc.2013.05.019","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093\/eurheartj\/ehw128","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1155-1168. doi:10.1016\/j.healun.2018.07.022","DOI":"10.1016\/j.healun.2018.07.022"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Takeda K, Li B, Garan AR, et al. Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. J Heart Lung Transplant. 2017;36(6):650-656. doi:10.1016\/j.healun.2016.12.006","DOI":"10.1016\/j.healun.2016.12.006"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1264-1277. doi:10.1016\/j.healun.2015.08.014","DOI":"10.1016\/j.healun.2015.08.014"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327-340. doi:10.1016\/j.healun.2014.02.027","DOI":"10.1016\/j.healun.2014.02.027"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Sabatino M, Vitale G, Manfredini V, et al. Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. J Heart Lung Transplant. 2017;36(11):1217-1225. doi:10.1016\/j.healun.2017.02.014","DOI":"10.1016\/j.healun.2017.02.014"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Quader M, Hawkins RB, Mehaffey JH, et al. Primary graft dysfunction after heart transplantation: Outcomes and resource utilization. J Card Surg. 2019;34(12):1519-1525. doi:10.1111\/jocs.14274","DOI":"10.1111\/jocs.14274"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Santise G, Panarello G, Ruperto C, et al. Extracorporeal membrane oxygenation for graft failure after heart transplantation: a multidisciplinary approach to maximize weaning rate. Int J Artif Organs. 2014;37(9):706-714. doi:10.5301\/ijao.5000353","DOI":"10.5301\/ijao.5000353"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. D'Alessandro C, Golmard JL, Barreda E, et al. Predictive risk factors for primary graft failure requiring temporary extra-corporeal membrane oxygenation support after cardiac transplantation in adults. Eur J Cardiothorac Surg. 2011;40(4):962-969. doi:10.1016\/j.ejcts.2011.01.064","DOI":"10.1016\/j.ejcts.2011.01.064"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Mehdiani A, Immohr MB, Boettger C, et al. Extracorporeal membrane oxygenation after heart transplantation: impact of type of cannulation. Thorac Cardiovasc Surg. 2020. doi:10.1055\/s-0039-3400472","DOI":"10.1055\/s-0039-3400472"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. DeRoo SC, Takayama H, Nemeth S, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after heart transplant. J Thorac Cardiovasc Surg. 2019;158(6):1576-1584 e1573. doi:10.1016\/j.jtcvs.2019.02.065","DOI":"10.1016\/j.jtcvs.2019.02.065"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Lo Coco V, Lorusso R, Raffa GM, et al. Clinical complications during veno-arterial extracorporeal membrane oxigenation in post-cardiotomy and non post-cardiotomy shock: still the Achille's heel. J Thorac Dis. 2018;10(12):6993-7004. doi:10.21037\/jtd.2018.11.103","DOI":"10.21037\/jtd.2018.11.103"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Conte SM, Florisson DS, De Bono JA, Davies RA, Newcomb AE. Levosimendan following cardiac surgery. Heart Lung Circ. 2019;28(3):e19-e20. doi:10.1016\/j.hlc.2018.02.018","DOI":"10.1016\/j.hlc.2018.02.018"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Wang B, He X, Gong Y, Cheng B. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: an update meta-analysis and trial sequential analysis. Biomed Res Int. 2018;2018:7563083. doi:10.1155\/2018\/7563083","DOI":"10.1155\/2018\/7563083"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Putzu A, Clivio S, Belletti A, Cassina T. Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. Int J Cardiol. 2018;251:22-31. doi:10.1016\/j.ijcard.2017.10.077","DOI":"10.1016\/j.ijcard.2017.10.077"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Guarracino F, Heringlake M, Cholley B, et al. Use of levosimendan in cardiac surgery: an update after the LEVO-CTS, CHEETAH, and LICORN Trials in the light of clinical practice. J Cardiovasc Pharmacol. 2018;71(1):1-9. doi:10.1097\/FJC.0000000000000551","DOI":"10.1097\/FJC.0000000000000551"},{"issue":"46","key":"ref17","doi-asserted-by":"publisher","first-page":"28584","DOI":"10.1016\/S0021-9258(19)61945-9","article-title":"A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study","volume":"269","author":"Pollesello","year":"1994","unstructured":"18. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269(46):28584-28590","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem. 2004;266(1-2):87-107. doi:10.1023\/b:mcbi.0000049141.37823.19","DOI":"10.1023\/B:MCBI.0000049141.37823.19"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013;38(5):341-349. doi:10.1111\/jcpt.12067","DOI":"10.1111\/jcpt.12067"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Immohr MB, Jenke A, Jahn A, et al. Exploring the pleiotropic effects of levosimendan: impact on systemic inflammatory parameters and molecular salvage path-ways by modulation of cytokine levels and tissue apoptosis rate. J Heart Cardiol. 2017;3(1):1-9. doi:10.15436\/2378-6914.17.1461","DOI":"10.15436\/2378-6914.17.1461"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Cholley B, Caruba T, Grosjean S, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: The LICORN randomized clinical trial. JAMA. 2017;318(6):548-556. doi:10.1001\/jama.2017.9973","DOI":"10.1001\/jama.2017.9973"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376(21):2032-2042. doi:10.1056\/NEJMoa1616218","DOI":"10.1056\/NEJMoa1616218"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376(21):2021-2031. doi:10.1056\/NEJMoa1616325","DOI":"10.1056\/NEJMoa1616325"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Cholley B, Levy B, Fellahi JL, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. 2019;23(1):385. doi:10.1186\/s13054-019-2674-4","DOI":"10.1186\/s13054-019-2674-4"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Jacky A, Rudiger A, Kruger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J Cardiothorac Vasc Anesth. 2018;32(5):2112-2119. doi:10.1053\/j.jvca.2018.04.019","DOI":"10.1053\/j.jvca.2018.04.019"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Affronti A, di Bella I, Carino D, Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59(6):554-557. doi:10.1097\/MAT.0b013e3182a4b32e","DOI":"10.1097\/MAT.0b013e3182a4b32e"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Vally S, Ferdynus C, Persichini R, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9(1):24. doi:10.1186\/s13613-019-0503-1","DOI":"10.1186\/s13613-019-0503-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Singh SSA, Dalzell JR, Berry C, Al-Attar N. Primary graft dysfunction after heart transplantation: a thorn amongst the roses. Heart Fail Rev. 2019;24(5):805-820. doi:10.1007\/s10741-019-09794-1","DOI":"10.1007\/s10741-019-09794-1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Beiras-Fernandez A, Kur F, Kaczmarek I, et al. Levosimendan for primary graft failure after heart transplantation: a 3-year follow-up. Transplant Proc. 2011;43(6):2260-2262. doi:10.1016\/j.transproceed.2011.05.021","DOI":"10.1016\/j.transproceed.2011.05.021"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Weis F, Beiras-Fernandez A, Kaczmarek I, et al. Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation. J Heart Lung Transplant. 2009;28(5):501-504. doi:10.1016\/j.healun.2009.01.017","DOI":"10.1016\/j.healun.2009.01.017"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Barisin S, Djuzel V, Barisin A, Rudez I. Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation. Wien Klin Wochenschr. 2014;126(15-16):495-499. doi:10.1007\/s00508-014-0528-2","DOI":"10.1007\/s00508-014-0528-2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Fukuhara S, Takeda K, Polanco AR, Takayama H, Naka Y. Prolonged continuous-flow left ventricular assist device support and posttransplantation outcomes: A new challenge. J Thorac Cardiovasc Surg. 2016;151(3):872-880 e875. doi:10.1016\/j.jtcvs.2015.10.024","DOI":"10.1016\/j.jtcvs.2015.10.024"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Takeda K, Takayama H, Kalesan B, et al. Outcome of cardiac transplantation in patients requiring prolonged continuous-flow left ventricular assist device support. J Heart Lung Transplant. 2015;34(1):89-99. doi:10.1016\/j.healun.2014.09.007","DOI":"10.1016\/j.healun.2014.09.007"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Immohr MB, Mehdiani A, Albert A, et al. Heart transplantation in patients with ventricular assist devices: Impacts of the implantation technique and support duration. J Card Surg. 2020;35(2):352-359. doi:10.1111\/jocs.14392","DOI":"10.1111\/jocs.14392"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Marasco SF, Kras A, Schulberg E, Vale M, Lee GA. Impact of warm ischemia time on survival after heart transplantation. Transplant Proc. 2012;44(5):1385-1389. doi:10.1016\/j.transproceed.2011.12.075","DOI":"10.1016\/j.transproceed.2011.12.075"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Banner NR, Thomas HL, Curnow E, et al. The importance of cold and warm cardiac ischemia for survival after heart transplantation. Transplantation. 2008;86(4):542-547. doi:10.1097\/TP.0b013e31818149b9","DOI":"10.1097\/TP.0b013e31818149b9"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Nicoara A, Ruffin D, Cooter M, et al. Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. Am J Transplant. 2018;18(6):1461-1470. doi:10.1111\/ajt.14588","DOI":"10.1111\/ajt.14588"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Smith M, Vukomanovic A, Brodie D, Thiagarajan R, Rycus P, Buscher H. Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the Extracorporeal Life Support Organization (ELSO) registry. Crit Care. 2017;21(1):45. doi:10.1186\/s13054-017-1633-1","DOI":"10.1186\/s13054-017-1633-1"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Jacob S, Lima B, Gonzalez-Stawinski GV, et al. Extracorporeal membrane oxygenation as a salvage therapy for patients with severe primary graft dysfunction after heart transplant. Clin Transplant. 2019;33(5):e13538. doi:10.1111\/ctr.13538","DOI":"10.1111\/ctr.13538"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic S, the European Association of Cardiothoracic A, Boer C, et al. 2017 EACTS\/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32(1):88-120. doi:10.1053\/j.jvca.2017.06.026","DOI":"10.1053\/j.jvca.2017.06.026"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Nam K, Jang EJ, Kim GH, et al. Perioperative red blood cell transfusion and mortality following heart transplantation: A retrospective nationwide population-based study between 2007 and 2016 in Korea. J Card Surg. 2019;34(10):927-932. doi:10.1111\/jocs.14148","DOI":"10.1111\/jocs.14148"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. Thongprayoon C, Cheungpasitporn W, Lertjitbanjong P, et al. Incidence and impact of acute kidney injury in patients receiving extracorporeal membrane oxygenation: a meta-analysis. J Clin Med. 2019;8(7):981 doi:10.3390\/jcm8070981","DOI":"10.3390\/jcm8070981"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Zhou C, Gong J, Chen D, Wang W, Liu M, Liu B. Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2016;67(3):408-416. doi:10.1053\/j.ajkd.2015.09.015","DOI":"10.1053\/j.ajkd.2015.09.015"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Avtaar Singh SS, Banner NR, Rushton S, Simon AR, Berry C, Al-Attar N. ISHLT primary graft dysfunction incidence, risk factors, and outcome: A UK National Study. Transplantation. 2019;103(2):336-343. doi:10.1097\/TP.0000000000002220","DOI":"10.1097\/TP.0000000000002220"},{"key":"ref45","unstructured":""}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T04:48:46Z","timestamp":1622522926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2021\/19\/5\/0\/473\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2020.0342","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}